Under the partnership, both companies will collaborate at BioCentriq's good manufacturing practice (GMP) facilities in New Jersey to produce Tevogen's proprietary COVID-19-targeted T cells. The goal is to achieve large-scale manufacturing of clinical-grade, allogeneic T-cell therapy.
The U.S. Food and Drug Administration (FDA) is currently reviewing Tevogen's investigational new drug (IND) application for the antigen-specific T-cell therapy. In upcoming trials, Tevogen will study its COVID-19-specific CD8+ T cells, TVGN-489, for the drug's safety and ability to recognize and eliminate COVID-19-infected cells.
Financial details of the partnership were not disclosed.
Copyright © 2021 scienceboard.net
Read Again https://www.scienceboard.net/index.aspx?sec=log&itemID=2328
Bagikan Berita Ini
Related Posts :
Titagarh Rail Systems-BHEL consortium bags contract from Indian Railways to manufacture 80 Vande Bharat trains - The Indian Express- TRSL-BHEL consortium inks contract with Indian Railways to manufacture 80 Vande Bharat sleeper train sets - Moneycontrol
- Apple Could Manufacture 18% Of All iPhones In India By 2025 - Apple (NASDAQ:AAPL) - Benzinga
- Grasshopper Manufacture's first Direct briefly teased its next game | VGC - Video Games Chronicle
- Rio Tinto and Gemco Rail to manufacture ore wagons in Pilbara region - International Railway Journal
0 Response to "Tevogen, BioCentriq partner to manufacture COVID-19 T-cell therapy - The Science Board"
Post a Comment